Figure 5.

Representative MDP‐derived Nod2 agonists. The chemical structures of MDP and representative Nod2 agonists are shown. In all structures, the MDP scaffold is highlighted in green. As seen with Nod1‐targeted molecules, an increase in lipophilicity has resulted in more potent agonists. Modifications such as esterification also have decreased side effects such as pyrogenicity observed with the parental MDP molecule. Moreover, departure from the MurNAc monosaccharide has yielded compounds with similar efficacy. n‐Bu, n‐butyl; Et, ethyl.